Seeking Alpha
 

Johnson & Johnson (JNJ)

- NYSE
  • Jun. 15, 2012, 6:10 PM
    Shares of orthopedics stocks rose today after privately held Biomet said FQ4 sales rose 3.4%. Industry sales have been weak as people delay hip and knee replacement surgeries in the weak economy. Biomet, which reports earlier than peers, is viewed as an indicator for the rest of the industry. The news boosted ZMH +4.2%, SYK +3.5%, WMGI +1.8%, JNJ +0.9%.
    | 1 Comment
  • Jun. 13, 2012, 9:20 AM
    J&J (JNJ) +1.5% as it receives a trio of upgrades, including one from JPM for the first time in four years. The bank raises J&J to to "overweight" from "neutral," citing the company's recently launched cancer, hepatitis and HIV drugs. Meanwhile, Jefferies increases J&J to "buy" and Raymond James to "outperform." (see also)
    | Comment!
  • Jun. 13, 2012, 2:44 AM
    U.S. regulators cleared J&J's (JNJ) $19.7B purchase of Synthes. The transaction will close tomorrow. A J&J subsidiary initiated ~$12.9B in accelerated buyback agreements to help finance the cash-and-stock acquisition. The Synthes deal will add $0.03-0.05 to 2012 EPS, a turnaround from prior forecast of a $0.22/share reduction. In 2013, it will add $0.10-0.15 to EPS, ex-certain items.
    | 1 Comment
  • Jun. 12, 2012, 11:41 AM
    These 20 stocks will do well no matter what, UBS says: SUN, KMI, NUE, MWV, MAS, IRM, WYNN, LEG, RAI, MO, BMY, JNJ, CINF, PBCT, SAI, PAYX, FTR, WIN, PGN, POM. These stocks boast strong dividend payouts, and "tend to provide the most consistent alpha without the need for more tactical management."
    | 9 Comments
  • Jun. 11, 2012, 4:29 PM
    Johnson & Johnson (JNJ) has won FTC approval to acquire Swiss medical device maker Synthes, more than a year after the deal was first announced. In exchange for the go-ahead, J&J promises to sell a product used to treat serious wrist fractures and other assets to Biomet. The EU approved the acquisition in April following a pledge by J&J to sell its trauma ops in the region. (earlier)
    | Comment!
  • Jun. 11, 2012, 5:35 AM
    J&J (JNJ) may announce this week that it has agreed to pay up to $2.2B to settle investigations into how it marketed its Risperdal antipsychotic treatment and other drugs, and claims it paid kickbacks to Omnicare (OCR), Bloomberg reports. The company will make a misdemeanor plea, with the deal including a criminal penalty of as much as $600M.
    | 3 Comments
  • Jun. 10, 2012, 3:21 AM
    Sanofi (SNY) and J&J (JNJ) present data for Type 2 diabetes treatments that show they're more effective in lowering blood-sugar levels than Merck's (MRK) $3.3B market leader Januvia. However, Lantus from Sanofi, which is already approved, and canagliflozin from J&J, which isn't, have their drawbacks.
    | Comment!
  • Jun. 8, 2012, 4:59 PM
    Johnson & Johnson (JNJ) says it expects to incur a special charge in Q2 of ~$600M to increase its accrual for the potential settlement of previously disclosed civil litigation matters related to Risperdal, Invega, Natrecor and Omnicare (OCR).
    | Comment!
  • Jun. 8, 2012, 9:04 AM
    The sell-off in Europe has left in its wake several dividend payers selling for better multiples and offering higher yields than their U.S. counterparts. At 4.82%, Novartis (NVS) yields 90 bps more than JNJ. France Telecom (FTE)  yields 14.9% with a PE of 6.4 vs. 23.4 for its peers. The full list.
    | 3 Comments
  • Jun. 5, 2012, 3:59 PM
    Pharmacyclics' (PCYC +5.2%) ibrutinib has substantial commercial potential, says Needham. After reviewing the data, Needham sees PCYC and collaborator Johnson & Johnson (JNJ -0.1%) being in a strong position given the drug's potential as both a front-line and relapsed or refractory agent. The firm believes a single-agent Phase 3 trial in front-line elderly chronic lymphocytic leukemia cases may be possible by the end of this year.
    | Comment!
  • Jun. 5, 2012, 12:41 PM
    J&J's (JNJ -0.35%) Ethicon unit yesterday said it intends to stop selling four vaginal mesh implants that are the subject of lawsuits from over 600 women, who say the devices caused them internal injuries. (previous)
    | 1 Comment
  • Jun. 4, 2012, 9:10 AM
    "You have the 10-year note at less than 1.5% and you have stocks like JNJ yielding almost 4%," says Marc Faber, making the case for stocks over bonds. "If you have a time horizon of 10 years, I believe you're going to make more money in JNJ than you will in (Treasurys)."
    | 9 Comments
  • Jun. 4, 2012, 8:58 AM
    Dendreon (DNDN) -8.6% premarket after data from Johnson & Johnson (JNJ) and Medivation (MDVN) at the ASCO conference increases competitive pressure for DNDN's Provenge cancer drug. Patients taking JNJ's Zytiga in a late-stage pre-chemo prostate cancer study lived 27.2 months vs. 21.7 months for Provenge.
    | Comment!
  • Jun. 3, 2012, 3:17 AM
    Drug companies have been presenting trial data at the American Society of Clinical Oncology meeting in Chicago. Showing good results are J&J's (JNJ) Zytiga for prostate cancer, Roche's (RHHBY.PK) T-DM1 and Avastin for breast and ovarian tumors respectively, Teva's (TEVA) Treanda for the immune system, and Bristol Myers' (BMY) BMS-936558 for lung, kidney and skin cancer.
    | 2 Comments
  • May. 31, 2012, 5:48 PM
    For what it's worth, Goldman analyst Jami Rubin thinks Johnson & Johnson (JNJ) would be more valuable if it split up than as one conglomerate: "On an operational basis, we believe that JNJ’s businesses, separated as independent companies, would benefit from being more focused and potentially achieve peer group performance levels or better."
    | 7 Comments
  • May. 31, 2012, 11:14 AM
    Johnson & Johnson (JNJ) files for FDA marketing approval of its Type 2 diabetes pill canagliflozin, which is one of J&J's most promising drug candidates. (PR)
    | Comment!
Visit Seeking Alpha's
JNJ vs. ETF Alternatives
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale ofproducts in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.